Agile completes patient recruitment in Twirla phase 3 SECURE clinical trial
The company will complete screening at participating sites in the next two weeks. Enrollment is anticipated to be completed by the end of the third quarter. Twirla is
Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and bupropion HCl) to treat agitation associated with dementia due to Alzheimer’s.
The agreement formalizes a relationship between QB3@953 and GSK’s Discovery Partnerships with Academia (DPAc) team and creates a new channel for DPAc to identify early-stage opportunities. The agreement
The Israeli patent application No. 207420 is entitled "Methods and Compositions for Treating Inflammatory Bowel Disease". Once granted, the patent is expected to be valid through at least